Steven Chamow, Ph.D. has over 20 years of experience in biopharmaceutical product development. Previously, he served as senior vice president of CMC at Intradigm Corporation, a private biopharmaceutical company focused on developing RNAi therapeutics. Prior to Intradigm, Steve was vice president of process sciences at Genitope Corporation and at Abgenix, Inc., where he established the company’s process sciences department and helped lead design and construction of its award- winning production facility in Fremont, CA. He also served as director of biopharmaceutical development at Scios, Inc. and as a scientist and senior scientist in Genentech’s process development department. During his career, Steve contributed to the development of three commercial biotherapeutics: Avastin®, Natrecor®, and Vectibix®. He is author or co-author of more than 45 scientific publications and patents, the co-editor of a 1999 book “Antibody Fusion Proteins,” and co- author of the book “Therapeutic Fc Fusion Proteins,” published in 2014. Steve earned a bachelor’s degree in biology from the University of California, Santa Cruz. He was awarded his doctorate degree in biochemistry by the University of California, Davis, and completed postdoctoral training at the National Institutes of Health.